ETEST OXACILLIN OX 256 US F100 In vitro diagnostic, a quantitative technique for determining the antimicrobial susceptibility of bacteria species.
Published December 27, 2017 · Recall initiated: April 13, 2017
Summary
FDA records medical device Class II recall Z-0264-2018, published December 27, 2017 and initiated April 13, 2017. Recalling firm: BioMerieux SA; Status: Terminated; Reported quantity: 1585 units; Lot: REF: 520558, Lot numbers: 1003059010, 1003315830, 1004071250, 1004818860 and 1004890400. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
QC failures (MIC out of range high) for S.aureus ATCC 29213 strain on ETEST OX 256 (OXACILLIN) Foam packaging (Ref. 520558, 520518) reported. The product behavior could lead to False Resistant results.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- BioMerieux SA
- Distributor
- Worldwide Distribution - USA (nationwide) and to the countries of : Algeria, Austria, Australia, Belarus, Bosnia-Herz., Canada, Croatia, Czech Republic, Egypt, Estonia, France, Georgia, Germany, Greece, Guam, Hong Kong, Hungary, India, Israel, Italy, Japan, Kuwait, Lebanon, Malta, Mexico, Netherlands, Nigeria, Peru, Philippines, Qatar, Russian Fed., Saudi Arabia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, United Kingdom and Utd.Arab Emir.
- Lot
- REF: 520558, Lot numbers: 1003059010, 1003315830, 1004071250, 1004818860 and 1004890400.
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- France
Related recalls
- FDAEMAG system Model/Catalog Number: 418591/418591U Product Description: Nucleic acid sample preparationNovember 4, 2026
- FDAMYLA software. Used to manage microbiology test workflow from the reception of requests to the transmission ofAugust 18, 2021
- FDAVIDAS FSH, Ref 30407-01, IVD, Rx. The firm name on the label is bioMerieux SA, France. For use on theJuly 4, 2018
- FDAThe VITEK® 2 Gram Positive Susceptibility Card is intended for use with the VITEK 2 Systems in clinicalJune 20, 2018
- FDAPrimera Negra, Artificial Vanilla Flavoring NET WT 4 OZ and 8 OZDecember 27, 2017
- FDAThe GMK knee system: designed for cemented use in total knee arthroplasty. Sphere and Primary Inserts withDecember 27, 2017
Questions about this recall
Was ETEST OXACILLIN OX 256 US F100 In vitro diagnostic, a quantitative technique for determining the antimicrobial susceptibility of bacteria species. recalled?
Yes. FDA published recall Z-0264-2018 on December 27, 2017. Reported hazard: QC failures (MIC out of range high) for S.aureus ATCC 29213 strain on ETEST OX 256 (OXACILLIN) Foam packaging (Ref. 520558, 520518) reported. The product behavior could lead to False Resistant results.
What should I do if I have this product?
Voluntary: Firm initiated · Letter